Prognosticheskoe znachenie dlitel'nogo ispol'zovaniya selektivnykh Mz-kholinolitikov bol'nymi sindromom razdrazhennoy kishki


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article is dedicated to the evaluation of the efficacy of antispasmodic drugs used in the treatment of patients with irritable bowel syndrome (IBS). According to the results of numerous studies, hyoscine butylbromide has a physiological effect on the secretory and motor functions of the gastrointestinal tract, can effectively eliminate these violations and reduces the number of relapses. The authors conclude: prolonged use of hyoscine butylbromide in the complex therapy of patients with IBS is not only safe, but also prognostically justified for these patients, because it contributes the recovery of visceral sensitivity and significantly reduces the incidence of recurrence of the disease.

Texto integral

Acesso é fechado

Bibliografia

  1. Johanson J.F. Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies. Neurogastroenterol. Motil. 2004; 16: 701-11.
  2. Camilleri M. Mechanisms in IBS: something old, something new, something borrowed. Neurogastroenterol. Motil. 2005; 16: 311-16.
  3. Leslie A. Samuels Pharmacotherapy Update: Hyoscine Butylbromide in the Treatment of Abdominal Spasms Clinical Medicine: Therapeutics. 2009; 1: 647-55.
  4. Nicolas Cenac, Christopher N. Andrews, Marinella Holzhausen et al. Role for protease activity in visceral pain in irritable bowel syndrome. J. Clin Invest. 2007; 117(3): 636-47.
  5. Ford A.C., Talley N.J. Advances in pathophysiology, diagnosis and treatment Nat. Rev. Gastroenterol. Hepatol. 2010; 10: 216-34.
  6. DuPont A.W., DuPont H.L. The intestinal microbiota and chronic disorders of the gut Nat. Rev. Gastroenterol. Hepatol. 2011; 10: 214-26.
  7. Natalie J. Wood Human gut microbiota can be readily cultured, manipulated and archived. Nature Reviews Gastroenterology & Hepatology. 201; 8: 241-60.
  8. Pimentel M. et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N. Engl. J. Med. 2011; 364: 22-32.
  9. Whelan. Kevin Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. -Current Opinion in Clinical Nutrition & Metabolic Care. 2011; 14(Issue 6): 581-87.
  10. Kummer W., Lips K.S., Pfeil I.U. The epithelial cholinergic system of the airways. Histochem Cell Biol. 2008; 130(2): 219-34.
  11. Wessler I. , Kirkpatrick C.J. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans, Br. J. Pharmacol. 2008; 154: (8): 1558- 71.
  12. Saeed Kolahian, Reinoud Gosens. Cholinergic Regulation of Airway Inflammation and Remodelling. J. Allergy. 2012; 1: 69-78.
  13. Lee K.J., Kim Y.B., Kim J.H., Kwon H.C. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J. Gastroenterol. Hepatol. 2008; 11: 1689-94.
  14. Wotta D.R., Wattenberg E.V., Langason R.B., el-Fakahany E.E. M1, M3 and Ms muscarinic receptors stimulate mitogen-activated protein kinase. Pharmacology. 2008; 4: 175-86.
  15. Eulalia de la Torre, Lilia Davel et al. Muscarinic receptors participation in angiogenic response induced by macrophages from mammary adenocarcinoma-bearing mice. Breast Cancer Research. 2005; 7: 345-52.
  16. Tytgat G.N. Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007; 67(9): 1343-57.
  17. Ge Z., Yuan Y., Zhang S., et al. Efficacy and tolerability of two oral hyoscine butylbromide formulations in Chinese patients with recur-rent episodes of self-reported gastric or intestinal spasm-like pain. Int. J. Clin. Pharmacol. Ther. 2011; 49(3): 198-205.
  18. Nigam P. Different therapeutic regimens in irritable bowel syndrome J. Assoc Physicians. 1984; 32( 12): 1041 -44.
  19. Schafer E., Ewe K. Efficacy and tolerability of Buscopan Plus, Buscopan, paracetamol and placebo in outpatients with IBS. Fortschr. Med. 1990; 108(25): 488-92.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2014

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies